Azitra, Inc. Retained Earnings
Azitra, Inc. (AZTR) had Retained Earnings of -$75.80 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-12
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$75.80M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$72.45M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$68.52M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$66.29M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$75.80M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | -$72.45M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | -$68.52M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | -$66.29M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$63.52M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | -$60.63M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | -$57.57M 10-K · filed 2026-02-27 | |
| 2024-09-30 | -$55.17M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$54.16M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | -$51.53M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | -$48.60M 10-K · filed 2025-02-24 | -$48.60M 10-K · filed 2024-03-15 |
| 2023-09-30 | -$46.14M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | -$44.20M 10-Q · filed 2023-08-14 | |
| 2022-12-31 | -$37.31M 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |